electrophysiology mapping News
-
First Patients in the U.S. Enrolled in Biosense Webster Clinical Study To Evaluate VARIPULSE™ Catheter for Atrial Fibrillation
Johnson & Johnson MedTech* announced today that Biosense Webster, Inc., a worldwide leader in the science and technology of cardiac arrhythmia treatment, enrolled the first patients in its admIRE clinical study in the United States. admIRE is a prospective, multi-center, non-randomized study that will enroll more than 400 patients in the U.S. to evaluate the safety and effectiveness of ...
-
CoreMap Wins National Science Foundation Phase 1 SBIR Award
CoreMap, Inc. announced today that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Science Foundation (NSF) to support development of its technology aimed at expanding treatment opportunities for patients with Atrial Fibrillation (AF). AF is the most common and complex cardiac arrythmia affecting 33 million patients globally where patients are at ...
By CoreMap Inc.
-
Acutus Medical completes enrollment in IDE trial with its AcQBlate FORCE Sensing Ablation System
Acutus Medical (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced successful completion of patient enrollment in the company’s AcQForce™ Flutter Investigational Device Exemption (IDE) clinical trial which enrolled 110 patients at 21 sites globally. The AcQForce Flutter trial was designed to ...
-
GALAXY Medical CENTAURI PEF Generator to be Used During Recorded Case Presentation at AF Symposium
SAN CARLOS, California, January 18, 2021 — Galaxy Medical, a developer of Pulsed Electric Field (PEF) technology for the treatment of cardiac arrhythmias, today announced that its proprietary CENTAURI™ System will be featured in a recorded case presentation on Sunday January 31st during the upcoming AF Symposium. Ante Ani, EP Lab Director at University Hospital Split and the Primary ...
-
Vektor Medical to Present Positive Results from vMap Clinical Validation Study Showing 97.3% Mapping Accuracy for Atrial and Ventricular Arrhythmias
Non-invasive arrhythmia technology maps using only the data from a 12 lead ECG vMap provides actionable mapping results in minutes. Blinded, multi-center study with analysis by an independent core laboratory Results to be presented for the first time at Heart Rhythm 2022 Vektor Medical today announced positive results from its “Vektor vMap™ Clinical Validation ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you